Strategic Diagnostics Position APRINOIA as a partner for neurodegenerative diagnostics, leveraging APN-1607 PET imaging tracer capabilities and the firm’s expertise in tau pathology to offer co development or blinded studies with pharma to enhance patient stratification and trial endpoints.

Contract Services Capitalize on recent launch of high-molecular-weight oligomer tau measurement service to offer CRO-like contract capabilities to biotechs and pharma seeking high-sensitivity tau assays, expanding revenue through service-based collaborations.

Early Stage Partnerships Target mid to late-stage biotech and pharma in neurology for joint development of imaging tools and biomarkers, leveraging APRINOIA’s Phase 3 progress and ADDF-backed credibility to de-risk co investment and licensing deals.

Public Market Momentum Leverage recent IPO activity and public listing status to engage investors and strategic buyers; explore equity partnerships, strategic collaborations, or out-licensing of APN-1607 and related imaging platforms to accelerate commercialization.

Global Expansion Highlight China-focused Phase 3 activities and partnerships (e.g., with Yantai Yitai) as a pathway to cross-border collaborations, distribution of imaging agents, and multi-regional trials that align with potential partner footprints and market access strategies.